The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of €4,155 million and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 578 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com
View Top Employees from MENARINI GroupWebsite | https://www.menarini.com |
Revenue | $31.2 million |
Employees | 10,405 (4,222 on RocketReach) |
Founded | 1886 |
Technologies |
JavaScript,
HTML,
Twitter
+85 more
(view full list)
|
Category | Pharmaceutical Manufacturing, Manufacturing General, ALLERGOLOGY, Manufacturing, ANDROLOGY, ANTINFECTIVE AREA, CARDIOVASCULAR AREAS, GASTROINTESTINAL DISORDERS, GYNECOLOGY AND WOMEN'S WELLNESS, PAIN, TRAUMA AND HEADACHES, RESPIRATORY AREA, REUMATOLOGY, FLU, COUGHS AND COLDS, DERMATOLOGY AND PERSONAL CARE, FOOD SUPPLEMENTS |
SIC | 2834, 283, 28 |
NAICS | 325, 32541, 3254, 32 |
Looking for a particular MENARINI Group employee's phone or email?
The MENARINI Group annual revenue was $31.2 million in 2023.
Francesco Michienzi is the Global Medico-Marketing Excellence Department Director in Menarini Group and President of Relife SRL of MENARINI Group.
4,222 people are employed at MENARINI Group.
The NAICS codes for MENARINI Group are [325, 32541, 3254, 32].
The SIC codes for MENARINI Group are [2834, 283, 28].